Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Long-Term Deferred Tax (2022 - 2025)

Sunshine Biopharma filings provide 4 years of Long-Term Deferred Tax readings, the most recent being $92234.0 for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $92234.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $92234.0, a N/A change, with the full-year FY2024 number at $481747.0, up 172.54% from a year prior.
  • Long-Term Deferred Tax hit $92234.0 in Q3 2025 for Sunshine Biopharma, roughly flat from $92234.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $481747.0 in Q4 2024 to a low of $92234.0 in Q1 2025.
  • Median Long-Term Deferred Tax over the past 4 years was $134499.0 (2023), compared with a mean of $206084.3.
  • Biggest five-year swings in Long-Term Deferred Tax: crashed 41.33% in 2023 and later soared 172.54% in 2024.
  • Sunshine Biopharma's Long-Term Deferred Tax stood at $301293.0 in 2022, then crashed by 41.33% to $176764.0 in 2023, then soared by 172.54% to $481747.0 in 2024, then crashed by 80.85% to $92234.0 in 2025.
  • The last three reported values for Long-Term Deferred Tax were $92234.0 (Q3 2025), $92234.0 (Q2 2025), and $92234.0 (Q1 2025) per Business Quant data.